Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP)
Fatigue is the most common symptom and the most disabling symptom of Multiple Sclerosis, and its inefficient management can be a source of multiple consultations (increase in health costs) and a reduction in productivity (work…
- Trial name
- SeDiF_SEP (NCT03662347)
- Where
- France
- Volunteers
- 2,100 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Sclerosis
Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.
The goal of this observational study is to evaluate the slowing/reduction of cognitive dysfunction progression and to evaluate grey matter (GM) and thalamus structural changes in Relapsing-Remitting Multiple Sclerosis (RRMS)…
- Trial name
- NCT05811949
- Testing
- Dimethyl Fumarate 240 MG [Tecfidera]
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis
Feasibility and Reliability of Multimodal Evoked Potentials
Multimodal Evoked potentials (mmEP) reflect disease course of multiple sclerosis (MS) and are potentially suited as a biomarker for disease progression.
- Trial name
- EP-B (NCT03686826)
- Testing
- Acquisition of MEP und SSEP
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases (CIDP Echo-nerf)
Chronic inflammatory demyelinating polyradiculoneuritis (CIDP) is an autoimmune disorder of the peripheral nervous system, most commonly affecting the myelin sheath.
- Trial name
- CIDP echo-nerf (NCT05257733)
- Testing
- None, pure observationnal study
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cultural Adaptation, Reliability
Turkish Version of F-2-MS
The aims of this study were to perform cultural adaptation of the F-2-MS and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking patients with Multiple Sclerosis.
- Conditions
- Cultural Adaptation, Reliability, Validity, Multiple Sclerosis
- Trial name
- NCT05590533
- Testing
- Cultural adaptation, reliability and validity
- Volunteers
- 180 people
- Sponsor
- Pamukkale University
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
- Trial name
- NCT04032158
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis, Covid19
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection.
- Trial name
- NCT04682548
- Where
- United States
- Volunteers
- 920 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Muscular Dystrophy
Enhance Wellness for Individuals With Long-Term Physical Disabilities
This project is an adaptation trial, testing the efficacy of an evidence-based community wellness program, Enhance Wellness (http://www.projectenhance.org/enhancewellness.aspx), in a sample of middle and older-aged adults living…
- Conditions
- Multiple Sclerosis, Muscular Dystrophy, Post-polio Syndrome, Spinal Cord Injury
- Trial name
- NCT02815878
- Testing
- Enhance Wellness
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Washington
Multiple Sclerosis
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Primary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing…
- Trial name
- TERIKIDS (NCT02201108)
- Testing
- Teriflunomide
- Where
- 57 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
This was a phase 2a study of MLN1202 to determine safety, tolerability and initial efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). It was conducted in 2 dose cohorts enrolling a total of 50 patients.
- Trial name
- NCT01199640
- Testing
- MLN1202
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
TBI (Traumatic Brain Injury) or MS (Multiple Sclerosis)
Improving Learning in Hispanics With TBI or MS
The goal of this study is to establish that a memory retraining protocol, originally developed for English-speakers, and translated into Spanish, is effective.
- Trial name
- NCT03453125
- Testing
- Spanish modified Story Memory Technique (mSMT)
- Where
- 2 sites in United States, Spain
- Volunteers
- 40 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Upper extremity (UE) function is critical to maintaining independence. Better understanding of UE involvement in MS will provide necessary information to prioritize the design and selection of future interventions.
- Trial name
- NCT02398149
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Mount Sinai Rehabilitation Hospital
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Multiple Sclerosis, Spinal Cord Injury
Power Over Pain (POP) Study
Many individuals with multiple sclerosis (MS), spinal cord injury (SCI), acquired amputation (AMP), muscular dystrophy (MD), and low back pain (LBP) experience pain. There has been little research on how to treat this pain.
- Conditions
- Multiple Sclerosis, Spinal Cord Injury, Chronic Pain, Other and Unspecified Amputation Stump Complications
- Trial name
- POP (NCT01800604)
- Testing
- Pain Self-Management Intervention #1, Pain Self-Management Intervention #2, Pain Self-Management Intervention #3
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Washington
Relapsing Remitting Multiple Sclerosis
Safety of New Formulation of Glatiramer Acetate
The purpose of this study is to compare pain associated with injections and injection-site reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA.
- Trial name
- Song (NCT00947752)
- Testing
- Glatiramer Acetate, Experimental Glatiramer Acetate
- Volunteers
- 147 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®).
- Trial name
- CARE-MS I (NCT00530348)
- Testing
- Alemtuzumab, Interferon beta-1a
- Where
- 101 sites in United States, Argentina and 14 more
- Volunteers
- 581 people
- Sponsor
- Genzyme, a Sanofi Company
Mental Health, Multiple Sclerosis
Upper Limb Function in Mental Health Disorders
Background: Individuals with mental disorders (MD) often experience motor issues, yet upper limb functionality remains understudied.
- Trial name
- UFMC-MH2025 (NCT06949449)
- Where
- Spain
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Universidad de Burgos
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen
Multiple Sclerosis
Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS
The primary objective is to assess the performance of a new magnetic resonance imaging (MRI) metrics software prototype when used in radiological practice in multiple sclerosis (MS).
- Trial name
- NCT04145284
- Where
- 2 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- Biogen
Guillain-Barre Syndrome, CIDP
Biomarkers in Polyradiculoneuropathies
The nodes of Ranvier contain ion channels that enable the rapid propagation of the nerve impulse. Cell adhesion molecules and glycolipids play an important role in the formation of the nodes of Ranvier.
- Trial name
- BIP (NCT04249752)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.